Medtronic (MDT) versus Integer (ITGR) Head-To-Head Survey
Medtronic (NYSE: MDT) and Integer (NYSE:ITGR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
Medtronic pays an annual dividend of $1.84 per share and has a dividend yield of 2.2%. Integer does not pay a dividend. Medtronic pays out 50.5% of its earnings in the form of a dividend. Integer has increased its dividend for 39 consecutive years.
Earnings and Valuation
This table compares Medtronic and Integer’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Medtronic||$29.71 billion||3.74||$4.03 billion||$3.64||22.53|
|Integer||$1.39 billion||1.04||$5.96 million||$0.63||72.62|
Medtronic has higher revenue and earnings than Integer. Medtronic is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Medtronic has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Integer has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Institutional & Insider Ownership
81.9% of Medtronic shares are held by institutional investors. Comparatively, 95.1% of Integer shares are held by institutional investors. 0.3% of Medtronic shares are held by insiders. Comparatively, 4.8% of Integer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of current ratings for Medtronic and Integer, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Medtronic currently has a consensus price target of $88.75, indicating a potential upside of 8.23%. Integer has a consensus price target of $51.00, indicating a potential upside of 11.48%. Given Integer’s higher possible upside, analysts plainly believe Integer is more favorable than Medtronic.
This table compares Medtronic and Integer’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Medtronic beats Integer on 11 of the 17 factors compared between the two stocks.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company’s subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Greatbatch, Inc. is a developer and manufacturer of medical devices and components. The Company operates through two segments: Greatbatch Medical and QiG Group (QiG). Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical’s products include medical devices and components for the cardiac, neuromodulation, orthopedics, portable medical, vascular and energy markets. QiG focuses on developing medical device systems for some of healthcare’s challenges and reflects the Company’s strategic evolution of its product offerings in order to raise the growth and profitability profile of the Company. QiG utilizes a diversified portfolio approach with three investment modes: new medical device systems commercialization, collaborative programs with OEM customers and strategic equity positions in emerging healthcare companies.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with Analyst Ratings Network's FREE daily email newsletter.